Effect of minimally invasive cardiac surgery on hospital length of stay: A systematic review and meta-analysis

D.F. Hoogma^{1,2,*}, T. van Bos¹, F. Polfliet³, P. Verbrugghe^{2,4}, W. Oosterlinck^{2,4}, J. Van den Eynde², S. Rex^{1,2}

¹University Hospitals Leuven, Department of Anesthesiology, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium; ²University of Leuven, Biomedical Sciences Group, Department of Cardiovascular Sciences, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; ³Jessa Hospital, Department of Anesthesiology, Stadsomvaart 11, 3500 Hasselt, Belgium; ⁴University Hospitals Leuven, Department of Cardiac Surgery, KU Leuven, Herestraat 49, 3000 Leuven, Belgium:

Corresponding author: Hoogma D.F., University Hospitals Leuven, Department of Anesthesiology, Department of Cardiovascular Sciences, Herestraat 49, 3000 Leuven, Belgium. E-mail: Danny.hoogma@uzleuven.be

Abstract

Background: Perioperative management using minimally invasive cardiac surgery (MICS), compared to full sternotomy (FS) cardiac surgery, is considered to improve postoperative recovery, and reduce hospital length of stay (LOS).

Methods: A comprehensive systematic search was conducted across MEDLINE/PubMed, Embase, and the Cochrane library to identify RCT comparing MICS to FS approach for aortic valve, mitral valve, and coronary artery bypass surgery. Meta-analysis of extracted data was performed using random effects models.

Results: A total of 33 RCTs including 2920 patients were identified. Overall MD (95% CI) for hospital and intensive care unit (ICU) LOS after MICS was significantly shorter compared to FS (-0.88 days (-1.55;-0.20), p<0.013; 2606 patients) and (-0.23 days (-0.41;-0.05), p=0.012; 2242 patients), respectively. Additionally, postoperative blood loss was reduced with the use of MICS, (-192.07 ml (-292.32;-91.82), p=0.002; 718 patients). There was no evidence for differences between both groups in terms of postoperative ventilation times, duration of surgery, reintervention rate, incidence of postoperative atrial fibrillation or stroke, hospital mortality, or 1-year mortality.

Conclusion: Within the limitations of a meta-analysis, MICS was found to be effective in promoting faster recovery by reducing postoperative blood loss, ICU, and hospital LOS.

Keywords: Enhanced recovery, minimally invasive, cardiac surgery, valve replacement, coronary bypass, ERACS.

Introduction

In cardiac surgery, the classical access to the heart is via a median full sternotomy which is usually well tolerated postoperatively¹. Nonetheless, sternotomy can result in moderate to severe postoperative pain affecting respiratory function, reducing ambulation and thus delaying hospital discharge². Several surgical and technical innovations have led to a dramatic decrease in surgical invasiveness and contributed in some populations to an improved outcome (i.e., wound healing in diabetic and obese patients)³⁻⁵. In the early 1990s, off-pump coronary artery bypass grafting (OPCAB) surgery was introduced, followed by the development of minimally invasive direct coronary artery bypass grafting (MIDCAB) in 1995⁶. In 1996, mitral valve surgery (MVS) through a thoracotomy, hence avoiding sternotomy, was described^{7,8}. Aortic valve replacement (AVR) through a right anterior thoracotomy was first presented in 1993 by Rao and Kumar⁹, with the combination of femoral cannulation in 1996 by Cosgrove¹⁰. Each of these minimally invasive and/or access techniques have further evolved by reducing invasiveness with the aim to improve recovery, reduce length of stay and hasten return to normal activities⁸. The minimally invasive approaches described above are considered fundamental elements in Enhanced Recovery After (Cardiac) Surgery (ERA(C)S) concepts^{11,12}. Mini thoracotomy, while a key element, may heighten the risk for intercostal nerve injury and postoperative pain². Moreover, minimally invasive procedures often hinder surgical exposure, increase complexity and present significant challenges for the surgeon, perfusionist and anesthetist¹³. Associated drawbacks include longer operating times, duration of cardiopulmonary bypass (CPB), and aortic cross-clamp, increased rates of bleeding and vascular complications, and redo thoracotomies^{2,14}. Consequently, there is concern about the heightened risks, such as stroke and aortic dissection/injury, particularly with femoral cannulation, emphasizing the need for careful consideration when opting for minimally invasive techniques^{15,16}.

Systematic reviews comparing minimally invasive cardiac surgery (MICS) to conventional surgery so far have generally stated that the evidence or quality of the included studies was generally poor^{14,17}. Moreover, data on the risk of stroke are conflicting^{2,16,18,19}. Furthermore, improved outcomes were often observed in only single or dual center studies²⁰. In addition, several meta-analyses did not assess cardiovascular morbidity and recovery. Lastly, these meta-analyses were mostly limited to the comparison of aortic valve surgery comparing full to hemi-sternotomy.

The goal of the present systematic review was to update the available evidence by assessing the impact of MICS on hospital length of stay (LOS) when compared to conventional cardiac surgery with full sternotomy. We hypothesized that MICS would be associated with a reduced hospital LOS and would be equally safe when compared to 'conventional cardiac surgery' using a 'full sternotomy'. We analyzed this for a wide range of cardiac interventions: AVR, MVS, OPCAB and on-pump coronary artery bypass grafting (CABG) surgery.

Material and methods

Eligibility criteria

Based on the PICOS strategy we included studies if: 1. The population comprised patients undergoing AVR, MVS or coronary bypass surgery; and

2. The interventional or experimental group had this intervention using a minimally invasive surgical (non-full sternotomy) approach; and

3. The control group was undergoing a conventional surgical approach with full sternotomy; and

4. Outcomes of the selected studies included any of the following: Primary outcome was hospital LOS as defined from the day of cardiac surgery until the day of discharge (in days). Secondary outcomes included all-cause mortality (in hospital, at 30 days and 1 year after surgery), the incidence of major adverse cardiac and cerebrovascular events (MACCE) [(in-hospital and in the first 6 postoperative months); i.e., death from any cause; perioperative myocardial infarction, requirement of surgical revisions at the coronary arteries; postoperative coronary angioplasty; and stroke], re-intervention rates during total hospital LOS (such as re-exploration for bleeding), rates of other cerebrovascular accidents not included in MACCE (transient ischemic attacks, reversible ischemic neurologic deficit), duration of surgery (minutes), ICU LOS (days), pain scores (by measurement of the visual analogue scale (VAS) or numeric rating scale (NRS) for pain scale), postoperative blood loss (milliliters), incidence of new onset atrial fibrillation AF and postoperative ventilation times (minutes); and

5. These were randomized controlled trials.

Sources of information

A systematic literature search was performed on April 4th, 2021, and in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)²¹ guidelines: Cochrane Central Register of Controlled Trials (CENTRAL) (2021, issue 4), PubMed, Embase and Web of Science. ClinicalTrials.gov database, World Health Organization international clinical trials registry platform search portal (ICTRP) and ResearchGate was searched for 'grey' literature and studies that were not yet identified. We double checked the reference lists of the included studies and related systematic reviews on the subject for additional references. We restricted our search to literature published in English, French, Dutch, or German. There were no restrictions on the date of publication.

Search

The search was constructed with the aid of an information specialist using MeSH (medical subject headings) terms. A detailed search strategy is provided in the <u>supplemental materials</u>. The protocol was registered a priori in PROSPERO (CRD42021234941).

Selection of studies

The records identified were deduplicated with Endnote²². Thereafter, Rayyan QCRI²³ was used

to screen and select abstracts. The selected titles were assessed for eligibility for final inclusion based on full text analysis. Studies were selected independently by two reviewers (DFH and FP). In case of conflict, a third author (SR) was consulted. This process is depicted in the PRISMA flow diagram (Figure 1)²⁴.

Data collection process and items

Two independent reviewers (DFH and FP) extracted study methodology, patient characteristics, procedural characteristics, outcomes, and key conclusions from the included studies.

Statistical plan:

Data collection process and items

A meta-analysis was conducted with randomized trials for our primary outcome and our secondary outcomes. Analyses were performed using the "metaphor" package (version 4.4-0) of R Statistical Software (version 4.3.1)²⁵.

Mean differences (MD) with 95% confidence interval (CI) were calculated for continuous outcomes, while odds ratios (OR) with 95% CI were assessed for binary outcomes²⁶. In case only sample sizes, median, range and/or interquartile ranges were reported, we used the method described by Wan to estimate the sample means and standard deviations²⁷. Forest plots were created to visually represent clinical outcomes.

Subgroup analysis

The following subgroups were further analyzed separately: aortic valve replacement (hemi sternotomy, mini sternotomy, thoracotomy or thoracoscopy vs full sternotomy), mitral valve surgery (minimally invasive approach vs full sternotomy) and coronary bypass surgery (MIDCAB vs OPCAB or CABG).




Fig. 1 — PRISMA 2020 flow diagram. # = overlap in reasons for exclusion.

Risk of bias in included studies

Two reviewers assessed possible bias of the included studies independently (DFH and FP). The criteria of the 'Cochrane handbook for systematic reviews of interventions' were used via the RoB 2 tool²⁸. Bias was graded as 'yes', 'probably yes', 'probably no', 'no' and 'no information'. Once these questions were answered, a risk-of-bias judgement was made describing low risk of bias, some concerns or high risk of bias. Disagreement was solved by a third author (SR). Funnel plots represent the analysis of publication bias, statistically analyzed by Egger's test and Begg and Mazumdar's test.

Results

Results of the search

We identified a total of 6107 citations, of which 124 studies were considered relevant based on title and abstract. Based on full text assessment, we identified 33 publications that fulfilled our eligibility criteria (Figure 1). However, 3 publications reported on the same patient population but differed regarding exclusion criteria and outcomes²⁹⁻³¹. Therefore, from these three studies, we primarily used the data from Gąsior et al, unless the relevant outcome was not reported but was included in one of the other two studies³⁰.

Study characteristics

The study and patient characteristics are reported in Table I and Supplementary Table I. A total of 2920 unique patients (MICS: 1464 patients, FS: 1456 patients) were included in 33 trials²⁹⁻⁶¹. The trials had randomized between 36 and 270 participants and had been performed between 1995 and 2021 in 18 countries (Austria, Brazil, Czech Republic, Egypt, France, Germany, India, Italy, The Netherlands, Poland, Russia, Serbia, South Korea, Spain, Sweden, Turkey, United Kingdom, and USA). A total of 16 trials had been performed on AVR, 7 trials on MVS and 8 trials on CABG surgery. Only 5 studies were multicenter trials^{33,35,38,39,57}. The intervention procedure (minimally invasive technique) had been performed through a 'mini sternotomy or upper sternotomy' in 16 studies, through a thoracotomy (lateral/anterolateral/right/ left/anterior) or thoracoscopy in 15 studies. In 58 patients the surgical procedure was converted from minimally invasive to full sternotomy due to technical, anesthetic or surgical complications. In the trial of Nair et al. eight patients were diverted from MICS to the FS group prior to surgical incision based on findings derived from intraoperative transesophageal ultrasound, nonetheless, these were analyzed based on intention-to-treat³⁹. Two

trials excluded 3 patients each due to inability for single lung ventilation or inability of positioning the experimental valve^{42,57}. Further details can be found in <u>Supplementary Table II</u>.

Risk of bias in the included studies

Application of the RoB 2 tool suggested that several trials had some concerns of bias (Figure 2). Considering that specific outcomes might have been reported differently, we assessed reporting bias at the study-level as has been recommended²⁸. We found that all studies included information on outcome measures that are considered important for the type of intervention. Detailed information regarding allocation, blinding, incomplete outcome data, and selective reporting can be found in <u>supplementary</u> <u>material</u>.

Synthesis of results

Length of stay

Hospital LOS was reported in 28 studies (2606 patients) but none of the studies reported any discharge criteria (Figure 3). The overall MD (95% CI) showed a significant reduction in hospital LOS in patients undergoing MICS compared to patients having a conventional full sternotomy (-0.88 days (-1,55;-0.20), p=0.013) (Table II). Amongst these studies, there was an important heterogeneity of treatment effect for hospital LOS (I² 91%, p < 0.001). Subgroup analysis revealed that this effect was largest following MVS and non-significant following CABG or AVR surgery. No publication bias was observed (Figure 4).

Duration of ICU LOS was reported in 25 trials including 2242 patients. Overall MD (95% CI) showed that the patient group having MICS, compared to those operated on by conventional full sternotomy, had a shorter ICU LOS (-0.23 days (-0.41;-0.05), p=0.012) (Figure 3). There was evidence of important heterogeneity of treatment effect (I² 88%, p<0.001). Subgroup analysis revealed that this effect was largest following MVS and non-significant following CABG or AVR surgery. Funnel plot assessment suggested potential publication bias (Figure 4).

Duration of surgery

Twenty-one studies (2036 patients) reported duration of surgery. Compared to patients who had a conventional full sternotomy, MD (95% CI) for surgical time showed no difference in patients with MICS (15.67 minutes (-0.91;32.32), p=0.064) (Supplementary figure S1). These studies showed an important heterogeneity of treatment effect. Funnel plot assessment did not show any publication bias (Supplementary figure S2). **Table I.** — Study characteristics of relevant studies identified for meta-analysis comparing minimally invasive with full sternotomy approach for patients undergoing aortic valve replacement, mitral valve surgery or coronary artery bypass surgery.

Author	Country	Procedure	Study period	Intervention	Control	Multicentric	Reported outcomes
			in the provide states of the s	MICS (N)	FS (N)	Yes/No	, r
Ahangar et al ⁶¹	India	AVR	09/2010-08/2012	30	30	No	Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Postoperative pain;
Aris et al ⁶⁰	Spain	AVR	1999, 4 months	20	20	No	Ventilation time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Mortality; Postoperative pain; Atrial fibrillation
Bauer et al ^{s9}	Germany	CABG	NR	50	50	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL;
Bonacchi et al ^{ss}	Italy	AVR	01/1999 - 07/2001	40	40	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Re-exploration rates; Mortality; Postoperative pain; Atrial fibrillation;
Borger et al ⁵⁷	USA, Germany	AVR	05/2012 - 08/2015	46	48	Yes	Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events;
Calderon et al ⁵⁶	France	AVR	01/2002 - 12/2006	39	38	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Postoperative pain;
Chahal et al ^{ss}	India	MVS	NR	25	25	No	Ventilation time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events;
Dalén et al ⁵⁴	Sweden	AVR	10/2016 - 08/2015	19	21	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Stroke; Atrial fibrillation;
Dias et al ⁵³	Brazil	AVR	06/1997 - 08/1998	20	20	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Postoperative pain;

Dogan et al ⁵⁰	Germany	CABG	NR	19	20	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Postoperative pain;
Dogan et al ^{s1}	Germany	AVR	NR	20	20	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Postoperative pain;
Dogan et al ⁵²	Germany	MVS	NR	20	20	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Stroke;
El-Fiky et al49	Egypt	MVS	NR	50	50	No	Surgery time in minutes; Hospital stay in days; Blood loss in mL;
Foik et al ²⁹	Poland	CABG	11/2009 - 12/2013	92	108	No	Mortality; Atrial fibrillation;
Ganyukov et al48	Russia	CABG	12/2012 - 11/2017	52	50	No	Hospital stay in days; Mortality; Major adverse cardiac and cere- brovascular events;
Gasior et al ³⁰	Poland	CABG	11/2003 - 10/2013	98	102	No	Hospital stay in days; Blood loss in mL; Mortality; Major adverse cardiac and cere- brovascular events;
Gofus et al ⁴⁷	Czech Re- public	AVR	05/2017 - 11/2019	20	20	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Stroke; Atrial fibrillation
Gu et al ⁴⁶	The Nether- lands	CABG	06/1995 - 06/1996	31	31	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Blood loss in mL;
Gulielmos et al45	Germany	CABG	NR	17	19	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Mortality; Atrial fibrillation;
Hancock et al ⁴⁴	United King- dom	AVR	03/2014 - 07/2016	135	135	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Postoperative pain; Stroke; Atrial fibrillation

Iyigün et al43	Turkey	CABG	05/2013 - 01/2015	33	29	No	Hospital stay in days; Intensive care unit stay in days;
Kang et al ⁴²	South Korea	MVS	11/2010 - 03/2011	50	50	No	Ventilation time in minutes; Intensive care unit stay in days;
Mächler et al41	Austria	AVR	07/1996 - 12/1997	60	60	No	Surgery time in minutes; Blood loss in mL; Mortality; Major adverse cardiac and cere- brovascular events;
Moustafa et al40	Egypt	AVR	NR	30	30	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates;
Nair et al ³⁹	United King- dom	AVR	01/2010 - 04/2015	118	104	Yes	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Mortality; Major adverse cardiac and cere- brovascular events; Postoperative pain;
Nasso et al ³⁸	Italy	MVS	01/2008 - 01/2012	80	80	Yes	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Mortality; Major adverse cardiac and cere- brovascular events;
Nourelden et al ³⁷	Egypt	MVS	05/2017 -04/2019	25	25	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Postoperative pain; Atrial fibrillation
Rodriguez- Caulo et al ³⁶	Spain	AVR	03/2016 - 05/2018	50	50	No	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Atrial fibrillation
Rogers et al ³⁵	United King- dom, Italy	CABG	02/2007 - 11/2009	91	93	Yes	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Postoperative pain; Stroke; Atrial fibrillation
Schneider et al ³⁴	Russia	AVR	2012 - 2017	56	56	No	Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Re-exploration rates; Mortality; Major adverse cardiac and cerebrovascular events;

Speziale et al ³³	Italy	MVS	01/2006- NR	70	70	Yes	Ventilation time in minutes; Surgery time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Postoperative pain;
Tajstra et al ³¹	Poland	CABG	11/2009 - 10/2013	94	97	No	Mortality; Major adverse cardiac and cere- brovascular events;
Vukovic et al ³²	Serbia	AVR	02/2016 - 11/2017	50	50	No	Ventilation time in minutes; Hospital stay in days; Intensive care unit stay in days; Blood loss in mL; Re-exploration rates; Mortality; Major adverse cardiac and cere- brovascular events; Atrial fibrillation

			<u>D1</u>	<u>D2</u>	D3	<u>D4</u>	D5	<u>Overall</u>		
Ahangar et al	2013	AVR		+	+	+	!		+	Low risk
Aris et al	1999	AVR	-	+	+	+	!	+	!	Some concerns
Bauer et al	2001	CABG	+	+	+	+		+	-	High risk
Bonacchi et al	2002	AVR	+	+	+	+	+	+		
Borger et al	2016	AVR		!	+	•	+		D1	Randomisation process
Calderon et al	2009	AVR	+	+	+	+	•		D2	Deviations from the intended interventions
Chalal et al	2016	MVS	+	+	+	+	•	+	D3	Missing outcome data
Dalen et al	2018	AVR	+	+	+	+	+	+	D4	Measurement of the outcome
Dias et al	1999	AVR	+	+	+	+	•	+	D5	Selection of the reported result
Dogan et al 2002	2002	CABG	•	+	+	+				
Dogan et al 2003	2003	AVR	•	+	+	+	+	+		
Dogan et al 2005	2005	MVS	-	+	+	+	1	+		
El-Fiky et al	2000	MVS	+	+	+	+	1	+		
Ganyukov et al	2020	CABG	+	+	+	+	+	+		
Gasior et al	2014	CABG	+	•	+	+	+	-		
Gofus et al	2020	AVR	-	+	+	+	1			
Gu et al	1999	CABG	-	+	+	+	1			
Gulielmos et al	1999	CABG	-	•	+	+	1			
Hancock et al	2021	AVR	+	+	+	+	+	+		
lyigun et al	2017	CABG	+	+	+	+	1	+		
Kang et al	2011	MVS	+	+	+	+	1	+		
Mächler et al	1999	AVR	-	+	+	+	1			
Moustafa et al	2007	AVR	•	+	+	+	!			
Nair et al	2018	AVR	+	•	+	+	+			
Nasso et al	2014	MVS	+	+	+	+	•	+		
Nourelden et al	2020	MVS	•	+	+	+	+			
Rodriguez-caulo et al	2020	AVR	+	+	+	+	+	+		
Rogers et al	2012	CABG	+	•	+	+	+			
Shneider et al	2020	AVR	•	+	+	+	!			
Speziale et al	2011	MVS	+	+	+	+	!	+		
Vukovic et al	2019	AVR	+	+	+	+	!	+		

Fig. 2 — Risk of bias summary.

AVR, aortic valve replacement; CABG, coronary artery bypass grafting; MVS, mitral valve surgery.

Ventilation time

Twenty-three studies reported ventilation time, including 2071 patients. The MD (95% CI) showed that ventilation time tended to be reduced in patients who had MICS compared to full sternotomy, although this was non-significant (-183,19 minutes (-379.1;10,72), p=0.063) (Supplementary figure S1). These studies showed an important

heterogeneity of treatment effect. Funnel plot assessment did not show any publication bias (Supplementary figure S2).

Complications

Postoperative blood loss

Eleven studies (718 patients) reported postoperative blood loss. Compared to patients

operated on by full sternotomy, MD (95% CI) postoperative blood loss was significantly reduced in patients with MICS (-192.07 ml (-292.32;-91.82), p=0.002) (Supplementary figure S3). These studies showed an important heterogeneity of treatment effect. Funnel plot assessment did not show any publication bias (Supplementary figure S4).

Re-intervention

Twenty studies (1899 patients) reported reintervention rate. Compared to patients operated on by full sternotomy, re-intervention rate was not different in patients with MICS (<u>Supplementary</u> figure S3). There was no evidence of heterogeneity of treatment effect. Funnel plot assessment did not show any publication bias (<u>Supplementary</u> figure S4).

Mortality

In-hospital mortality was reported by 19 studies including 1655 patients. No significant difference was observed in in-hospital mortality between patients with MICS or full sternotomy (Figure 5). Seven studies, including 692 patients, reported 30-day mortality. Compared to patients who had a conventional full sternotomy, no significant difference was observed in 30-day mortality in patients with MICS (Figure 5). Ten studies, including 1282 patients, reported 1-year mortality. No significant difference was observed in 1-year mortality between the groups (Figure 5). No evidence of heterogeneity of treatment effect was observed in the mortality analyses. Funnel plot assessment did not show any publication bias (Supplementary figure S5).

New onset atrial fibrillation

Eleven studies (1102 patients) reported the incidence of new onset AF. Incidence of new onset AF was not different between the two groups (Supplementary figure S6). There was no evidence of heterogeneity of treatment effect. Funnel plot assessment did not show any publication bias (Supplementary figure S7).

Major adverse cardiac and cerebrovascular events

Only 1 study reported on MACCE. Seventeen studies, including 2013 patients reported stroke, and seven studies (996 patients) reported cerebrovascular accidents not included in MACCE. No significant difference was observed in the occurrence of either outcome in patients with MICS compared to those operated on by conventional full sternotomy (Supplementary figure S6). There was no evidence of heterogeneity of treatment effect for stroke or cerebrovascular accidents not included in MACCE. Assessment of funnel plots did not show any publication bias (Supplementary figure S7).

Postoperative pain

Six studies (973 patients) described pain scores between the two groups for pain scores on postoperative day 1. These studies showed an important heterogeneity of treatment effect. Subgroup analysis identified a low heterogeneity following AVR surgery with a statistically significant reduction in pain scores in favor of MICS (Supplementary figure S8).

Five studies (749 patients) reported pain scores between the two groups for pain scores on postoperative day 2. Subgroup analysis, including 4 studies, identified a low heterogeneity following AVR surgery without any difference in pain scores. Two studies (492 patients) described pain scores on postoperative day 3 following AVR surgery and three studies (312 patients) on postoperative day 5. No significant difference was observed in pain scores at the given time points (<u>Supplementary figure S8</u>). Assessment of funnel plot did not show any publication bias (<u>Supplementary figure S9</u>).

Discussion

Summary of main results

General belief is that MICS ensures better outcomes when compared to traditional full sternotomy surgery. Given the ongoing technological advancements and the widespread awareness of these options among the general population, surgeons nowadays find themselves compelled to adopt these techniques, despite the long learning curves^{4,5}.

The findings of our systematic review and metaanalysis indicate that MICS is linked to a reduction in ICU and hospital LOS. Moreover, there is a significant decrease in postoperative blood loss following MICS whilst no difference can be detected in procedural and postoperative ventilation time. Additionally, the results demonstrate no differences in reintervention rates, incidences MACCE, new onset AF, or mortality (Table II).

Resource restraints have prompted changes in postsurgical management, aiming to "fast-track" cardiac surgical patients⁶². Traditionally, next to the use of minimal access, early postoperative extubation was a key component in this approach, suggested to reduce ICU LOS. Although we did not identify a reduction in postoperative ventilation times, we found a modest yet significant reduction in ICU

ERACS BENEFITS FROM MINIMALLY INVASIVE SURGERY – HOOGMA et al. 205

Weight Weight 95%-Cl (fixed) (random)	0.3% 6.1% 0.2% 5.1% 0.5% 5.0% 0.5% 7.5% 14.0% 0.5% 0.0% 0.5% 0.1% 3.2%	1.4% 5.0% 0.3% 6.0% 0.0% 0.9% 0.0% 0.2% 0.2% 5.7% 0.2% 0.7% 0.2% 5.7%	← (1	$\begin{array}{cccccccccccccccccccccccccccccccccccc$.0% 100.0%
	[-0.37, 0.07] [-0.64, 0.42] [-0.58, -0.02] [-0.20; 0.12] [-0.03, 0.03] [-1.16, 1.16] [-1.16, 1.16] [-1.30; -0.50] [-0.50]	[-0.04, 0.10] [-0.04, 0.160] [-1.09, 0.64] [-0.34, 0.14] [-0.34, 0.14] [-0.52, 1.52] [-0.05, 0.01] [-0.42, 0.07]	[-0.77; 0.40] [-0.48; 0.68] [-0.48; 0.03] [-0.46; 0.14] [-0.04; -0.01] [-0.04; -0.02] [-0.04; -0.02]	[-0.35] [-0.32] [-0.22] 0.23] [-0.43; -0.77] [-1.43; -0.77] [-1.43; -0.77] [-1.54; -0.45] [-1.54; -0.46]	0.03 [-0.04; -0.02] 100.0% -0.23 [-0.41; -0.05]
ference MD	- - - - - - - - - - - - - - - - - - -				-0.03 -0.23 -0.23
Mean Difference	·····	+ +			-3 -2 -
Sternotomy Fotal Mean SD	30 1.24 0.54 20 1.94 1.00 40 1.40 0.80 38 2.04 0.50 38 2.04 0.50 20 2.75 2.30 20 2.01 0.90 20 0.00 20 0.00 00 0.90	1.00 1.15 1.44 5.06 5.06 2.30 2.30	1.00 0.99 0.94 0.94	25 4.82 3.52 20 1.60 1.10 50 1.40 0.55 80 3.20 1.10 25 3.68 1.52 70 3.20 1.10 270 3.20 1.10	1115 < 0.001) 0 (<i>p</i> = 0.012) 5.5 0 df - 3 (n 2 0
Winimally invasive Sternotomy Total Mean SD Total Mean SD	30 1.09 0.30 20 1.83 0.70 39 2.00 0.40 19 1.00 0.05 20 2.75 1.30 20 1.20 0.10 20 1.20 0.10 20 1.20 0.10	1.12 1.90 0.28 3.65 2.30 2.30 2.80 2.80	0.81 1.30 0.93 0.92 0.92	25 2.83 1.18 20 1.30 0.90 50 1.30 0.90 80 2.10 1.00 25 2.40 1.08 70 2.10 0.90 270	1127 < 0.001 = 4.84 (p - effect): $z_2 = -4.84$ (p - om effects): $t_{24} = -2.7$ om effects): $t_{24} = -2.7$
B Mi Study T	Group = AVR Ahangar 2013 Aris 1999 Bonacchi 2002 Calderon 2009 Dalen 2018 Dias 1999 Dogan 2003 Gofus 2020	$\begin{array}{c} \mbox{cons}\ 2021 \\ \mbox{cons}\ 2021 \\ \mbox{marce}\ 2021 \\ \mbox{marce}\ 2007 \\ \mbox{marce}\ 2018 \\ \mbox{marce}\ 2018 \\ \mbox{configure}\ 2019 \\ \mbox{cons}\ 50 \\ \mbox{cons}\ 50 \\ \mbox{fixed effect model} \\ \mbox{Fixed effect model} \\ \mbox{fandom effects model} \\ \mbox{Heterogeneity}\ \ell^2 = 86\%, \ \rho < 0.00 \\ \mbox{Heterogeneity}\ \ell^2 = 0.000 \end{array}$	$ \begin{array}{l} \mbox{Group} = CABG \\ \mbox{Bauer 2001} \\ \mbox{Bauer 2002} \\ \mbox{Dogan 2002} \\ \mbox{Oldimos 1999} \\ \mbox{Oldimos 1017} \\ \mbox{Oldimos 2012} $	$\begin{array}{c} \mbox{Commal 2016} & 25 \\ \mbox{Commal 2016} & 25 \\ \mbox{Kang 2011} & 50 \\ \mbox{Narsso 2014} & 80 \\ \mbox{Narsso 2014} & 80 \\ \mbox{Narsso 2014} & 25 \\ \mbox{Narseles 2011} & 70 \\ \mbox{Fixed effect model} & 270 \\ \mbox{Fixed effect model} & 270 \\ \mbox{Random effects model} & 270 \\ Random effects mode$	Fixed effect model 1127 1115 Random effects model 120 120 Heterogeneity: $I^2 = 88\%$, $p < 0.001$ -3 Test for overall effect (fixed effect): $z = -4.84$ ($p < 0.001$) -3 Test for overall effect (random effects): $I_2 = -2.70$ ($p = 0.012$) -3 Test for overall effect (random effects): $I_2 = -2.70$ ($p = 0.012$) -3
Weight random)	5.1% 2.8% 5.5% 6.1% 3.1% 5.8%	5.2% 6.2% 1.0% 2.9% 53.2%	5.2% 2.9% 3.7% 5.3% 6.2% 3.1.9%	2.0% 0.6% 2.5% 2.5% 2.5%	 100.0%
Weight Weight MD 95%-CI (fixed) (random)	[-1.72; [-1.46; [-1.46; [-1.87; [-0.67; [-0.35; [-0.35; [-0.89; [-0.89;	[-0.28] 2.48] [-12.83, -6.57] [-135, -1.05] [-5.80, -1.05] [-5.80, -1.30] [-5.80, -1.30] [-5.80, -1.30] [-5.80, -1.80] [-3.14], -0.26] [-0.89], -0.67] [-1.81], -0.38]	0.30 [-0.88; 0.28] 1.1% 2.70 [1.28; 4.12] 0.2% 0.30 [-2.01; 1.41] 0.1% 3.30 [-1.43] 2.2% 0.30 [-1.43; 1.28] 0.2% 0.30 [-0.86; 0.26] 1.2% 0.30 [-0.86; 0.26] 1.2% 0.30 [-0.86; 0.26] 1.2% 0.74 [-0.81; 0.66] 67.4% 0.661 [-1.94; 0.73]	2.48 [-4.44; -0.52] 0.1% -1.20 [-5.26; 2.86] 0.0% 0.00 [-0.78; 0.78] 0.6% -3.10 [-4.57; -1.63] 0.2% -3.20 [-4.68, -3.40] 0.1% -3.20 [-4.64; -1.56] 0.1% -1.67 [-2.23; -1.11] 1.2% -2.54 [-4.42; -0.67]	-0.76 [-0.82; -0.70] 100.0% -0.88 [-1.55; -0.20]
Mean Difference	+ +	+ 	+ + +		
Sternotomy otal Mean SD		6.30 9.80 9.30 9.30 9.30	50 3.90 1.80 20 6.60 1.30 50 13.80 4.41 31 7.70 2.60 19 6.40 0.80 229 9.03 2.91 93 6.00 0.33 334	25 9.12 4.54 20 9.10 8.30 50 7.00 2.00 80 11.60 5.00 25 11.04 5.20 70 11.80 5.20	
Minimally invasive Sterno Total Mean SD Total Mean	1.00 2.30 1.60 0.17 3.00 1.00	7.40 7.50 8.00 0.83 8.60 0.50 8.38 4.06 14.10 5.10 7.60 2.00	3.60 1.10 9.30 2.90 13.50 4.41 8.80 4.30 4.40 1.70 6.10 0.90 5.25 0.17	6.64 2.09 7.90 4.10 7.00 2.00 8.50 4.50 6.04 1.10 8.60 4.70	z = -24.57 (p ts: ts= -26.57
Σ	Group = AVR Ahangar 2013 Aris 1999 Benacchi 2002 Calderon 2009 Dalen 2018 Dias 1999 Dogan 2003 Gotus 2020	Harook 2021 135 Harook 2021 135 Moustata 2007 30 Rodriguez-Caulo 2018 118 Schneider 2020 56 Vukovic 2019 56 Fixed effect model 647 Random effects model 647 Hetrogeneity: $l^{5} = 93\%$, $p < 0.001$	$ \begin{array}{l} \label{eq:constraint} \text{Reserved} \\ \begin{tabular}{lllllllllllllllllllllllllllllllllll$	Group = MVR 25 Dogan 2016 25 Dogan 2005 20 ELFiky 2000 50 Nasso 2014 80 Nasso 2014 80 Nasso 2014 25 Speciale 2011 70 Fixed effect model 270 Fixed effect model 2400	Fixed effect model 1308 Fixed effect model 1308 Random effects model 0.001 Heterogeneity: $f^{2} = 3\%, \rho < 0.001$ Test for overall effect (fixed effect): Test for overall effect (fixed effect):

Fig. 3—Forrest plots with pooled mean difference for (A) hospital and (B) intensive care unit length of stay. AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CI, confidence interval; MD, mean difference; MVR, mitral valve replacement/repair.

Table II. — Summary of findings: Full sternotomy compared to minimally invasive cardiac surgery in adults.

Patient or population: adult patients requiring aortic valve replacement, mitral valve surgery or coronary artery bypass surgery. Settings: Cardiac surgical care, Intervention: minimally invasive cardiac surgery (partial sternotomy, thoracotomy or thoracoscopic access); Comparison: full sternotomy cardiac surgery.

Outcomes No of participants (stud- ies)	Relative effect (95% CI)	Anticipated absolute effects ^a (95% CI)	ffects [#] (95% CI)		Certainty of the evidence (GRADE)	Comments
		Risk with FS	Risk with MICS	Difference		
Hospital LOS Follow-up: In-patient		Mean hospital LOS was 9 days		0.88 days shorter hospital LOS (1.55 to 0.20 fewer)	Low ^{1,2,3,4}	May decrease the hospi- tal LOS.
stay					Due to risk of bias, indi- rectness, and inconsistency	
2606 (28 studies)						
ICU LOS		The mean ICU LOS was 2 days		0.23 days shorter ICU LOS (0.41 to 0.05 fewer)	Very low ^{1,2,3,4}	May reduce the ICU LOS.
2242 (25 studies)					Due to risk of bias, indi- rectness, and inconsistency	
Duration of surgery (min)		The mean surgery time was 189 min-	-	15.67 minutes longer surgery time (0.97 fewer to 32.32 more)	Very low ^{1,3}	There may be an in- crease in surgery time.
2036 (21 studies)		utes			Due to inconsistency and variations in perioperative management	
Postoperative ventilation time (min)	1	The mean postopera- tive ventilation time	I	184 minutes shorter postoperative ventilation time	Very low ^{1,3}	May decrease postopera- tive ventilation time.
2071 (23 studies)		was 803 minutes		(379.10 fewer to 10.72 more)	Due to inconsistency and variations in perioperative management	
Postoperative blood loss		The mean postopera- tive blood loss was		192 mL fewer postoperative blood	Moderate ³	Probably decreases the
Follow-up: until remov- al of drains		573 mL		(292 to 92 lower)	Due to inconsistency	tive blood loss.
718 (11 studies)						
Reintervention rate Follow-up: In-patient stay	OR 0.82 (0.53 to 1.26)	53 per 1000	44 per 1000 (29 to 66)	1.0 % fewer reinterventions(2.6 fewer to 1.5 more)	Moderate⁴	There may be little or no difference in reinterven- tion rate.
1899 (20 studies)						

207

In-hospital mortality 1955 (19 studies)	OR 0.93 (0.39 to 2.19)	12 per 1000	11 per 1000 (5 to 26)	0.08 % fewer in-hospital mortality (0.74 fewer to 1.47 more)	Moderate ⁴	There may be little or no difference in in-hospital mortality.
30-day mortality 692 (7 studies)	OR 0.98 (0.46 to 2.11)	20 per 1000	20 per 1000 (9 to 41)	0.04 % fewer 30-day mortality (1.09 fewer to 2.32 more)	Moderate ⁴	There may be little or no difference in 30-day mortality.
1-year mortality 1282 (10 studies)	OR 1.10 (0.61 to 1.99)	31 per 1000	34 per 1000 (19 to 60)	0.32 % more 1-year mortality (1.23 fewer to 3.27 more)	Moderate ⁴	There may be little or no difference in 1-year mortality.
New onset AF Follow-up: In-patient stay 1102 (11 studies)	OR 1.01 (0.72 to 1.41)	252 per 1000	253 per 1000 (195 to 322)	0.34 % more new onset AF (8.62 fewer to 16 more)	Low ⁵ Due to imprecision	There may be little or no difference in new onset AF.
Postoperative day 1 pain score Follow-up: first day after surgery 973 (6 studies)		The mean pain score was 3.44		0.55 lower postoperative day 1 pain score (1.31 lower to 0.21 higher)	Very low ^{1.3.6} Due to indirectness	There may be little or no difference in postopera- tive pain scores.
Stroke 2013 (17 studies)	OR 1.05 (0.51 to 2.17)	13 per 1000	14 per 1000 (7 to 28)	0.07 % more stroke (0.64 fewer to 1.57 more)	Moderate ⁴ Due to imprecision	There may be little or no difference in mortality.
Cerebrovascular ac- cidents not included in MACCE 996 (7 studies)	OR 1.39 (0.57 to 3.37)	20 per 1000	28 per 1000 (11 to 64)	0.80 % more non-MACCE (0.87 fewer to 5.08 more)	Moderate ⁴ Due to imprecision	There may be little or no difference in cere- brovascular accidents not included in MACCE occurrence.
# The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the interv AF, atrial fibrillation; CI, confidence interval; FS, full stemotomy; ICU, intensive care unit; LOS, length of stay; MACCE, Major adverse card GRADE working group quality of evidence: Very low. We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Low: Our confidence in the effect estimate is limited: The true effect is likely to be close to the estimate of the effect. Low: Our confidence in the effect estimate is limited: The true effect is likely to be close to the estimate of the effect. Low: We are very confident in the effect estimate is limited. The true effect is likely to be close to the estimate of the effect. Explanations: I Downgraded for high risk of bias: outcome measure sensitive to lack of blinding in study; 2 Downgraded for high rest. Explanations: Explanations: I Downgraded for high risk of bias: outcome measure sensitive to lack of blinding in study; 2 Downgraded for high rest. Explanations: Explanations: I Downgraded for high risk of bias: outcome measure sensitive to lack of blinding in study; 2 Downgraded for high rest.	up (and its 95% CI) is bas nee interval; FS, full stern f evidence: fidence in the effect estim fidence in the effect estim fident in the effect estima t the true effect lies close ingh risk of bias: outcome	eed on the assumed risk in the c totomy, ICU, intensive care uni ate: The true effect is likely to true effect may be substantially to that of the estimate of the ef- to that of the estimate of the of a measure sensitive to lack of b	omparison group and the re it; LOS, length of stay; MA(be substantially different fra different from the estimate e close to the estimate of th Tect.	# The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). AF, atrial fibrillation; CI, confidence interval; FS, full stemotomy; ICU, intensive care unit; LOS, length of stay; MACCE, Major adverse cardiac and cerebrovascular events; MICS, minimally invasive cardiac surgery; OR, odds ratio; GRADE working group quality of evidence: Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Now: Owe more than the confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Now: We have very little confidence in the effect estimate is limited; The true effect is likely to be close to the estimate of the effect. Now: We are moderately confident in the effect estimate The true effect to be close to the estimate of the effect. Strong: We are very confident that the true effect lies close to that of the effect. Explanations: I Downgaded for high risk of bias: outcome measure sensitive to lack of blinding in study; 2 Downgraded for indirectness: length of stay is a surrogate marker of quality and (inter)nations exist in discharge	events; MICS, minimally invasive ca ntially different. e marker of quality and (inter)national	rdiac surgery, OR, odds ratio; variations exist in discharge

criteria; 3 Downgraded for inconsistency: variations in discharge criteria, anesthetic management and/or surgical technique might lead to a high heterogeneity; 4 Downgraded for imprecision: sample size did not meet Optimal Information Size criteria; 5 Downgraded for imprecision: wide 95% confidence intervals overlapping no effect; 6 Downgraded for indirectness: different measures of pain used across studies.

LOS in patients undergoing MICS, primarily driven by patients undergoing mitral valve surgery^{33,37,38,42,52,55}. This finding aligns with a recent review describing a significant reduction in ICU LOS⁶³. Patients undergoing surgery through minimally invasive access, as opposed to full sternotomy, face fewer mobility restrictions. This influences the behavior of healthcare personnel, potentially leading to patients being extubated at the end of surgery, expediting their ICU course and hospital LOS. Unfortunately, none of the included studies reported any discharge criteria.

Nevertheless, there is a prevailing belief that a minimal access limits visibility and increases complexity, consequently prolonging the duration of surgery⁶³. These challenges may counterbalance any potential advantages derived from MICS. Dieberg et al.'s review lends support to this perception by noting longer durations spent on CPB and in the operating theatre⁶⁴. In contrast, our analysis revealed no disparity in surgical times, not even in the subgroup analysis. We suggest that this finding can be most likely attributed to the increasing familiarity of the surgical community with the different MICS techniques. Another commonly cited criticism is the tendency to select only low-risk cases for MICS. However, the demographics of patients in the included randomized controlled studies were well balanced, and most trials used an intention-to-treat analysis.

Our analysis revealed comparable postoperative ventilation times for patients undergoing MICS and those undergoing full sternotomy cardiac surgery. The review of Dieberg et al. identified similar results with no significant differences between the two groups⁶⁴. Clearly, achieving blinding of healthcare providers for surgical access is challenging (if not impossible), so that the assessed outcomes are prone to bias, which might explain the large intergroup differences in several studies^{33,38}. Additionally, this difference may also reflect various institutional standard practices, given that MICS is considered a core intervention of enhanced recovery after surgery, often coupled to early postoperative extubation⁶⁵.

Early morbidity, including postoperative bleeding, is not uncommon after cardiac surgery, exposing patients to potential disruption in recovery and prolonging hospital LOS. The finding of reduced blood loss in patients undergoing MICS is thus promising. Elimination of the need for sternotomy has been suggested as the reason for reduced blood loss⁶³. However, our subgroup analysis revealed that hemi-sternotomy (as compared to full sternotomy for AVR), also resulted in reduced blood loss. Another possible explanation could be heightened attention to meticulous hemostasis in case of MICS, partially due to the increased risk of tamponade from minor blood loss following the procedure.

New onset AF post cardiac surgery is a frequent adverse event. The etiology of AF is considered multifactorial, with a causal link to systemic inflammatory response following valve surgery^{66,67}. Importantly, new onset AF has been linked to an increase in ICU LOS, hospital LOS and additional postoperative complications, including mortality. Our review found no difference between MICS or conventional full sternotomy surgery.

Overall completeness, quality, and applicability of evidence

We conducted a comprehensive search and uncovered several RCTs that were overlooked in Dieberg et al.'s search⁶⁴. Despite similarities in inclusion criteria, Dieberg et al.'s review encompassed prospective non-randomized studies and RCTs comparing MICS to conventional full sternotomy, while excluding hybrid procedures⁶⁴. In adhering to these criteria, we pinpointed eleven additional RCTs that meet their inclusion/exclusion criteria, indicating the depth of our search to be more exhaustive.

The population included in the different trials typically were exposed to surgical techniques consistent with standard practice. Nonetheless, ERACS programs, goal-directed cardiopulmonary bypass perfusion strategies, hybrid revascularization and/or transcatheter techniques are emerging






Fig. 4 — Funnel plots representing publication bias for (A) hospital and (B) intensive care unit length of stay.





options that had not been implemented routinely in the trials that were included in this review. Most trials reported outcome rates which correlate with equivalent data in the literature. This suggests that the teams involved (surgeon, anesthesiologist, and nurses) had sufficient experience with the different surgical techniques.

Limitations and strengths

The current meta-analysis has several limitations. Firstly, our analysis revealed significant heterogeneity, primarily stemming from variations in surgical techniques (e.g., robotic assistance), perioperative practices, and the definitions employed. While the inclusion and exclusion criteria across different trials were similar, variations in pathology (aortic, mitral, or coronary) or CPB techniques may have introduced additional differences. Furthermore, trials in CABG surgery generally excluded patients for participation if anatomy was unfavorable for either treatment arm, limiting generalizability. None of the trial protocols or published papers provided details on transfusion triggers, extubation criteria, ERACS concepts, or discharge criteria from the ICU or hospital, although these aspects were expected to be consistent within studies. Moreover, multiple of the assessed outcomes are prone to observer bias, downgrading the certainty of the evidence (Table II). Last, we cannot exclude the possibility of publication bias, as multiple trials have been registered but are either not completed or were unsuccessful regarding MICS. Last, absence of evidence does not necessarily indicate evidence of absence. The majority of included studies were probably underpowered to detect significant differences, at least in the secondary outcomes. Hence, our findings must be interpreted with caution.

This review has also several strengths. The current meta-analysis has been performed in a transparent and reproducible manner. The protocol for this meta-analysis was registered prior to the literature search and should have reduced any risk of bias in this review. Secondly, in contrast to Dieberg et al., we only included RCTs whereas these authors also included prospective trials in which patients were assigned to either treatment arm depending on preferences of the surgeon and patient⁶⁸. This seriously affects outcome assessment due to selection bias.

Conclusion

Implications for practice

This meta-analysis demonstrates that MICS reduces ICU and hospital LOS when compared to conventional cardiac surgery. Prolonged procedural

times and increased neurological complications are frequently brought forward as a major disadvantage of MICS. However, our review shows that these arguments are unfounded. Reduced postoperative blood loss, ICU, and hospital LOS, suggest that MICS is effective in promoting faster recovery.

Implications for research

The study suggests that minimally invasive techniques may reduce hospital and intensive care unit LOS without increasing mortality or morbidity in cardiac surgery. However, overall quality of evidence is rated as generally low to moderate, primarily due to small sample sizes, clinical heterogeneity, and, in some cases, statistical heterogeneity. While hospital LOS is considered a useful (surrogate) marker of postoperative recovery, the current trials have failed to describe their discharge criteria. Last, future research should focus on quality-of life assessments, well defined discharge criteria, and cost analysis to enhance the robustness of these findings.

Acknowledgments: The authors thank the dataspecialist of the Learning Centre Désiré Collen for their invaluable assistance in building our search strategy.

Contributions of authors:

DFH: Conceptualization, methodology, data curation, validation, supervision, writing - original draft, writing - review & editing.

TvB: Validation, writing - original draft

FP: Data curation, investigation, writing – original draft.

PV: Writing - review & editing.

WO: Writing - review & editing.

JVdE: Formal analysis, visualization, writing - review & editing.

SR: Resources, writing - review & editing.

All authors critically revised the manuscript draft and read and approved the final version.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data Availability Statement: All relevant data are within the manuscript and/or Supporting Information files.

Conflict of interest: None declared.

Differences between protocol and review: All-cause mortality 6 months: no data. OR instead of RR for dichotomous data.

References

- Lee BY, Gleason TG, Sonnad SS. Quality of life after aortic valve replacement. Expert Rev Pharmacoecon Outcomes Res. Jun 2004;4(3):265-75. doi:10.1586/14737167.4.3.265
- 2. Walther T, Falk V, Metz S, et al. Pain and quality of life after minimally invasive versus conventional cardiac surgery.

Ann Thorac Surg. Jun 1999;67(6):1643-7. doi:10.1016/ s0003-4975(99)00284-2

- Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine. 2011;364(23):2187-2198. doi:10.1056/NEJMoa1103510
- Cerny S, Oosterlinck W, Onan B, et al. Robotic Cardiac Surgery in Europe: Status 2020. Front Cardiovasc Med. 2021;8:827515. doi:10.3389/fevm.2021.827515
- 5. Mori M, Parsons N, Krane M, et al. Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation. Ann Thorac Surg. Jan 2024;117(1):96-104. doi:10.1016/j. athoracsur.2023.07.047
- Calafiore AM, Angelini GD. Left anterior small thoracotomy (LAST) for coronary artery revascularisation. Lancet. Jan 27 1996;347(8996):263-4. doi:10.1016/s0140-6736(96)90439-0
- Navia JL, Cosgrove DM, 3rd. Minimally invasive mitral valve operations. Ann Thorac Surg. Nov 1996;62(5):1542-4. doi:10.1016/0003-4975(96)00779-5
- Cohn LH, Adams DH, Couper GS, et al. Minimally invasive cardiac valve surgery improves patient satisfaction while reducing costs of cardiac valve replacement and repair. Ann Surg. Oct 1997;226(4):421-6; discussion 427-8. doi:10.1097/0000658-199710000-00003
- 9. Rao PN, Kumar AS. Aortic valve replacement through right thoracotomy. Tex Heart Inst J. 1993;20(4):307-8.
- Cosgrove DM, 3rd, Sabik JF. Minimally invasive approach for aortic valve operations. Ann Thorac Surg. Aug 1996;62(2):596-7.
- Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Review. Br J Anaesth. May 1997;78(5):606-17. doi:10.1093/bja/78.5.606
- Engelman DT, Ben Ali W, Williams JB, et al. Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations. Meta-Analysis. JAMA surgery. Aug 01 2019;154(8):755-766. doi:10.1001/ jamasurg.2019.1153
- Malik V, Jha AK, Kapoor PM. Anesthetic challenges in minimally invasive cardiac surgery: Are we moving in a right direction? Ann Card Anaesth. Jul-Sep 2016;19(3):489-97. doi:10.4103/0971-9784.185539
- Doenst T, Diab M, Sponholz C, Bauer M, Farber G. The Opportunities and Limitations of Minimally Invasive Cardiac Surgery. Review. Dtsch Arztebl Int. Nov 17 2017;114(46):777-784. doi:10.3238/arztebl.2017.0777
- Di Eusanio M, Vessella W, Carozza R, et al. Ultra fast-track minimally invasive aortic valve replacement: going beyond reduced incisions. European Journal of Cardio-Thoracic Surgery. 2018;53(suppl_2):ii14-ii18. doi:10.1093/ejcts/ ezx508
- Algarni KD, Suri RM, Schaff H. Minimally invasive mitral valve surgery: Does it make a difference? Trends in Cardiovascular Medicine. 2015;25(5):456-465. doi:10.1016/j.tcm.2014.12.007
- Kirmani BH, Jones SG, Malaisrie SC, Chung DA, Williams RJ. Limited versus full sternotomy for aortic valve replacement. Meta-Analysis. Cochrane Database Syst Rev. Apr 10 2017;4(4):CD011793. doi:10.1002/14651858. CD011793.pub2
- Cao C, Gupta S, Chandrakumar D, et al. A meta-analysis of minimally invasive versus conventional mitral valve repair for patients with degenerative mitral disease. Review. Ann Cardiothorac Surg. Nov 2013;2(6):693-703. doi:10.3978/j. issn.2225-319X.2013.11.08
- Sündermann SH, Sromicki J, Rodriguez Cetina Biefer H, et al. Mitral valve surgery: right lateral minithoracotomy or sternotomy? A systematic review and meta-analysis. J Thorac Cardiovasc Surg. Nov 2014;148(5):1989-1995.e4. doi:10.1016/j.jtcvs.2014.01.046
- Kikuchi K, Mori M. Minimally invasive coronary artery bypass grafting: a systematic review. Review. Asian Cardiovasc Thorac Ann. Jun 2017;25(5):364-370. doi:10.1177/0218492317692465

- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Mar 29 2021;372:n71. doi:10.1136/bmj.n71
- 22. Endnote Version Endnote X9. Clarivate; 2013.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews. 2016;5(1)doi:10.1186/s13643-016-0384-4
- 24. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLOS Medicine. 2021;18(3):e1003583. doi:10.1371/journal.pmed.1003583
- 25. A language and environment for statistical computing. R Foundation for Statistical Computing. Version 4.0.2 2020-06-22. 2020. http://www.r-project.org/index.html
- Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. International Journal of Evidence-Based Healthcare. Sep 01 2015;13(3):196-207. doi:10.1097/XEB.00000000000000055
- 27. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology. 2014;14(1):135. doi:10.1186/1471-2288-14-135
- Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4. The Cochrane Collaboration. Updated August 2023. Accessed 25-12-2023, 2023. https://training.cochrane.org/handbook/ current
- 29. Foik J, Brzek A, Gierlotka MJ, Zembala MO, Gasior M, Zembala M. Effect of hybrid treatment on rehabilitation and clinical condition of patients with multivessel coronary artery disease. Comparative Study. Pol Arch Intern Med. Feb 28 2018;128(2):77-88. doi:10.20452/pamw.4179
- 30. Gasior M, Zembala MO, Tajstra M, et al. Hybrid revascularization for multivessel coronary artery disease. Comparative Study. JACC Cardiovasc Interv. Nov 2014;7(11):1277-83. doi:10.1016/j.jcin.2014.05.025
- 31. Tajstra M, Hrapkowicz T, Hawranek M, et al. Hybrid Coronary Revascularization in Selected Patients With Multivessel Disease: 5-Year Clinical Outcomes of the Prospective Randomized Pilot Study. Randomized Controlled Trial. JACC Cardiovasc Interv. May 14 2018;11(9):847-852. doi:10.1016/j.jcin.2018.01.271
- 32. Vukovic PM, Milojevic P, Stojanovic I, et al. The role of ministernotomy in aortic valve surgery-A prospective randomized study. Comparative Study. J Card Surg. Jun 2019;34(6):435-439. doi:10.1111/jocs.14053
- 33. Speziale G, Nasso G, Esposito G, et al. Results of mitral valve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus conventional median sternotomy: a randomized trial. Comparative Study. J Thorac Cardiovasc Surg. Jul 2011;142(1):77-83. doi:10.1016/j. jtcvs.2010.08.033
- 34. Shneider YA, Tsoi MD, Fomenko MS, Pavlov AA, Shilenko PA. Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results. Comparative Study. Khirurgiia (Mosk). 2020;(7):25-30. doi:10.17116/hirurgia202007125
- 35. Rogers CA, Pike K, Angelini GD, et al. An open randomized controlled trial of median sternotomy versus anterolateral left thoracotomy on morbidity and health care resource use in patients having off-pump coronary artery bypass surgery: the Sternotomy Versus Thoracotomy (STET) trial. J Thorac Cardiovasc Surg. Aug 2013;146(2):306-16 e1-9. doi:10.1016/j.jtcvs.2012.04.020
- 36. Rodriguez-Caulo EA, Guijarro-Contreras A, Guzon A, et al. Quality of Life After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement. Randomized Controlled Trial. Semin Thorac Cardiovasc Surg. Summer 2021;33(2):328-334. doi:10.1053/j.semtcvs.2020.07.013

- 37. Nourelden E, El-Minshawy A, Ghoneim A, Alaa M, Shieba Y. Postoperative Outcomes of Minimally Invasive versus Conventional Mitral Valve Repair; A Randomized Study. Microsoft® Word 2016 Document. The Egyptian Cardiothoracic Surgeon. Mar 01 2021;3(2):44-50. doi:10.35810/ects.v3i2.176
- 38. Nasso G, Bonifazi R, Romano V, et al. Three-year results of repaired Barlow mitral valves via right minithoracotomy versus median sternotomy in a randomized trial. Comparative Study. Cardiology. 2014;128(2):97-105. doi:10.1159/000357263
- 39. Nair SK, Sudarshan CD, Thorpe BS, et al. Mini-Stern Trial: A randomized trial comparing mini-sternotomy to full median sternotomy for aortic valve replacement. Comparative Study. J Thorac Cardiovasc Surg. Dec 2018;156(6):2124-2132 e31. doi:10.1016/j.jtcvs.2018.05.057
- 40. Moustafa MA, Abdelsamad AA, Zakaria G, Omarah MM. Minimal vs median sternotomy for aortic valve replacement. Randomized Controlled Trial. Asian Cardiovasc Thorac Ann. Dec 2007;15(6):472-5. doi:10.1177/021849230701500605
- 41. Machler HE, Bergmann P, Anelli-Monti M, et al. Minimally invasive versus conventional aortic valve operations: a prospective study in 120 patients. Clinical Trial. Ann Thorac Surg. Apr 1999;67(4):1001-5. doi:10.1016/s0003-4975(99)00072-7
- 42. Kang WS, Yoon TG, Kim TY, Kim SH. Comparison of the PaO2/FiO2 ratio in sternotomy vs. thoracotomy in mitral valve repair: a randomised controlled trial. Comparative Study. Eur J Anaesthesiol. Nov 2011;28(11):807-12. doi:10.1097/EJA.0b013e32834ad993
- 43. Iyigun T, Kaya M, Gulbeyaz SO, et al. Patient body image, self-esteem, and cosmetic results of minimally invasive robotic cardiac surgery. Randomized Controlled Trial. Int J Surg. Mar 2017;39:88-94. doi:10.1016/j.ijsu.2017.01.105
- 44. Hancock HC, Maier RH, Kasim A, et al. Mini-sternotomy versus conventional sternotomy for aortic valve replacement: a randomised controlled trial. Randomized Controlled Trial. BMJ Open. Jan 29 2021;11(1):e041398. doi:10.1136/bmjopen-2020-041398
- 45. Gulielmos V, Eller M, Thiele S, et al. Influence of median sternotomy on the psychosomatic outcome in coronary artery single-vessel bypass grafting. Clinical Trial. Eur J Cardiothorac Surg. Nov 1999;16 Suppl 2:S34-8.
- 46. Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Clinical Trial. Ann Thorac Surg. Feb 1998;65(2):420-4. doi:10.1016/s0003-4975(97)01127-2
- 47. Gofus J, Vobornik M, Koblizek V, et al. Pulmonary function and quality of life after aortic valve replacement through ministernotomy: a prospective randomized study. Randomized Controlled Trial. Kardiol Pol. Dec 23 2020;78(12):1278-1280. doi:10.33963/KP.15668
- 48. Ganyukov V, Kochergin N, Shilov A, et al. Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year-Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS). Randomized Controlled Trial. J Interv Cardiol. 2020;2020:5458064. doi:10.1155/2020/5458064
- 49. El-Fiky MM, El-Sayegh T, El-Beishry AS, et al. Limited right anterolateral thoracotomy for mitral valve surgery. Clinical Trial. Eur J Cardiothorac Surg. Jun 2000;17(6):710-3. doi:10.1016/s1010-7940(00)00429-2
- Dogan S, Graubitz K, Aybek T, et al. How safe is the port access technique in minimally invasive coronary artery bypass grafting? Clinical Trial. Ann Thorac Surg. Nov 2002;74(5):1537-43; discussion 1543. doi:10.1016/s0003-4975(02)03947-4
- 51. Dogan S, Dzemali O, Wimmer-Greinecker G, et al. Minimally invasive versus conventional aortic valve

replacement: a prospective randomized trial. Clinical Trial. J Heart Valve Dis. Jan 2003;12(1):76-80.

- 52. Dogan S, Aybek T, Risteski PS, et al. Minimally invasive port access versus conventional mitral valve surgery: prospective randomized study. Clinical Trial. Ann Thorac Surg. Feb 2005;79(2):492-8. doi:10.1016/j. athoracsur.2004.08.066
- 53. Dias RR, Sobral MLP, Avelar JÚNior SF, et al. Cirurgia da valva aórtica: estudo prospectivo e randomizado da miniesternotomia versus cirurgia convencional. Revista Brasileira de Cirurgia Cardiovascular. Apr 06 1999;14(2):1-8. doi:10.1590/s0102-76381999000200005
- 54. Dalen M, Oliveira Da Silva C, Sartipy U, et al. Comparison of right ventricular function after ministernotomy and full sternotomy aortic valve replacement: a randomized study. Comparative Study. Interact Cardiovasc Thorac Surg. May 1 2018;26(5):790-797. doi:10.1093/icvts/ivx422
- 55. Chahal AK, Gehlaut P, Johar S, et al. "A Prospective Randomized Case-Control Study To Evaluate Mini Right Thoracotomy versus Conventional Sternotomy For Mitral Valve Repair In Rheumatic Heart Disease.". World Journal of Cardiovascular Surgery. Nov 04 2016;06(11):139-152. doi:10.4236/wjcs.2016.611021
- 56. Calderon J, Richebe P, Guibaud JP, et al. Prospective randomized study of early pulmonary evaluation of patients scheduled for aortic valve surgery performed by ministernotomy or total median sternotomy. Comparative Study. J Cardiothorac Vasc Anesth. Dec 2009;23(6):795-801. doi:10.1053/j.jvca.2009.03.011
- 57. Borger MA, Dohmen PM, Knosalla C, et al. Haemodynamic benefits of rapid deployment aortic valve replacement via a minimally invasive approach: 1-year results of a prospective multicentre randomized controlled trial. Multicenter Study. Eur J Cardiothorac Surg. Oct 2016;50(4):713-720. doi:10.1093/ejcts/ezw042
- 58. Bonacchi M, Prifti E, Giunti G, Frati G, Sani G. Does ministernotomy improve postoperative outcome in aortic valve operation? A prospective randomized study. Clinical Trial. Ann Thorac Surg. Feb 2002;73(2):460-5; discussion 465-6. doi:10.1016/s0003-4975(01)03402-6
- 59. Bauer M, Pasic M, Ewert R, Hetzer R. Ministernotomy versus complete sternotomy for coronary bypass operations: no difference in postoperative pulmonary function. Clinical Trial. J Thorac Cardiovasc Surg. Apr 2001;121(4):702-7. doi:10.1067/mtc.2001.111380
- 60. Aris A, Camara ML, Montiel J, Delgado LJ, Galan J, Litvan H. Ministernotomy versus median sternotomy for aortic valve replacement: a prospective, randomized study. Clinical Trial. Ann Thorac Surg. Jun 1999;67(6):1583-7; discussion 1587-8. doi:10.1016/s0003-4975(99)00362-8
- 61. Ahangar AG, Charag AH, Wani ML, et al. Comparing Aortic Valve Replacement through Right Anterolateral Thoracotomy with Median Sternotomy. Int Cardiovasc Res J. Sep 2013;7(3):90-4. doi:10.1136/bmj.326.7380.88
- 62. Ramakrishna H, Patel PA, Gutsche JT, et al. Surgical Aortic Valve Replacement—Clinical Update on Recent Advances in the Contemporary Era. YJCAN. Dec 01 2016;30(6):1733-1741. doi:10.1053/j.jvca.2016.04.014
- 63. Sa M, Van den Eynde J, Cavalcanti LRP, et al. Mitral valve repair with minimally invasive approaches vs sternotomy: A meta-analysis of early and late results in randomized and matched observational studies. Review. J Card Surg. Sep 2020;35(9):2307-2323. doi:10.1111/jocs.14799
- 64. Dieberg G, Smart NA, King N. Minimally invasive cardiac surgery: A systematic review and meta-analysis. Meta-Analysis. Int J Cardiol. Nov 15 2016;223:554-560. doi:10.1016/j.ijcard.2016.08.227
- 65. Zaouter C, Damphousse R, Moore A, Stevens LM, Gauthier A, Carrier FM. Elements not Graded in the Cardiac Enhanced Recovery After Surgery Guidelines Might Improve Postoperative Outcome: A Comprehensive Narrative Review. Review. J Cardiothorac Vasc Anesth. Mar 2022;36(3):746-765. doi:10.1053/j.jvca.2021.01.035

- 66. Greenberg JW, Lancaster TS, Schuessler RB, Melby SJ. Postoperative atrial fibrillation following cardiac surgery: a persistent complication. Eur J Cardiothorac Surg. Oct 1 2017;52(4):665-672. doi:10.1093/ejcts/ezx039
- 67. Anselmi A, Possati G, Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg. Jul 2009;88(1):326-33. doi:10.1016/j.athoracsur.2009.01.031
- Karpuzoglu OE, Ozay B, Sener T, et al. Comparison of minimally invasive direct coronary artery bypass and offpump coronary artery bypass in single-vessel disease. Heart Surg Forum. Jan 2009;12(1):E39-43. doi:10.1532/ HSF98.20081068

doi.org/10.56126/75.3.52